Trial reportJournal of the National Cancer Institute2025
Group-based trajectories of health-related quality of life among pediatric patients with high-risk Hodgkin lymphoma.
Trial report in Journal of the National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02166463 (A Randomized Phase 3 Study of Brentuximab Vedotin), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundHealth-related quality of life (HRQoL) was recently demonstrated to improve throughout therapy for high-risk pediatric Hodgkin lymphoma (HL); however, average scores may not reflect individual differences. This study aimed to identify subgroups of patients with similar HRQoL trajectories from pre- to post-therapy.
methodsAHOD1331 trial participants aged 11-20 (n = 268; mean [SD] age = 15.6 [1.9]; 48% male) completed the Child Health Ratings Inventories-Global scale (HRQoL) prior to treatment, after cycle 2, after cycle 5, and the end of treatment. Group-based trajectory models (GBTMs) identified latent clusters of individuals with similar HRQoL patterns over time. Multivariable multinomial logistic regression estimated the association between a priori defined characteristics and membership in trajectory-based groups. Log-rank tests examined differences in post-T4 progression-free survival (PFS) by trajectory groups.
resultsGBTM identified 3 HRQoL groups: Group 1 (consistently unfavorable [25.7%]), Group 2 (moderate-and-increasing [44.8%]), and Group 3 (consistently favorable [29.5%]). Older age (odds ratio = 1.24, 95% confidence interval = 1.03 to 1.50; P = .022), female sex (2.48, 1.23 to 4.99; P = .011), and Hispanic ethnicity (2.31, 0.97 to 5.50; P = .059) were associated with increased odds of membership in Group 1 vs Group 3. Older age (1.18, 1.00 to 1.39; P = .038) and B-symptoms (2.18, 1.09 to 4.33; P = .027) were associated with increased odds of Group 2 membership vs Group 3. Group membership was not associated with post-T4 PFS.
conclusionsA subgroup of high-risk pediatric HL patients experience persistently poor HRQoL, starting at diagnosis and continuing through therapy. Age, female sex, Hispanic ethnicity, and B-symptoms were linked to worse HRQoL. These findings can help identify patients at higher risk for poor HRQoL and guide intervention. CLINICALTRIALS.GOV: NCT02166463.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.